Kymera Therapeutics, Inc. (KYMR) Profit Margins
Over the twelve months to 2026-06-30, Kymera Therapeutics, Inc. (KYMR) had operating margin -333.5%, net margin -285.3%, free cash flow margin -226.6%, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
KYMRKymera Therapeutics, Inc.Follow KYMR — free
—
Price chart with a free account
- Market cap
- 9.2B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 29 Oct, in 5 days
| Line | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|
| Gross margin | — | — | — | — | 0.0% | 0.0% | — | |
| Operating margin | -136.1% | -138.0% | -344.4% | -210.6% | -555.8% | -891.1% | -333.5% | |
| Net margin | -134.0% | -137.6% | -330.6% | -187.0% | -475.6% | -794.0% | -285.3% | |
| FCF margin | 232.2% | -179.2% | -333.0% | -174.7% | -440.5% | -597.6% | -226.6% |
USD billions · SEC XBRL
Kymera Therapeutics, Inc. — questions
- What is Kymera Therapeutics, Inc.'s operating margin?
- -333.5% over the twelve months to 2026-06-30.
- What is Kymera Therapeutics, Inc.'s net profit margin?
- -285.3% over the twelve months to 2026-06-30.
Every figure on this page comes from Kymera Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.